Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of LT-02 add-on therapy in mesalamine-refractory ulcerative colitis
2012-003702-27Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing LT-02 add-on with Placebo add-on (2 arms). Primary endpoint: Clinical remission rate at 12 weeks. Started Dec 2013; status: completed.
02
Drugs
phosphatidylcholine (LT-02)
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2012-003702-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003702-27.